Skip to main
BBIO

BBIO Stock Forecast & Price Target

BBIO Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Pharma has demonstrated a strong financial outlook, with an updated full-year 2026 revenue forecast projected to rise to $766.3 million, reflecting positive momentum from its late-stage pipeline. The company is positioned for potential regulatory approvals for key candidates ribitol and encaleret in the first half of 2026, driven by robust clinical data suggesting an accelerated review process and favorable pricing opportunities. Additionally, the increase in the likelihood of approval for infigratinib in achondroplasia to 80% indicates a solid pipeline that could further enhance future revenue streams.

Bears say

BridgeBio Pharma's projected net loss for the full year 2025 stands at $3.59, indicating significant financial strain, particularly in the face of potential clinical and commercial setbacks that threaten its operational sustainability. The company is currently burdened by limited cash reserves and substantial debt, raising concerns about its ability to repay lenders and maintain operations in the event of unfavorable trial outcomes. Furthermore, competitive pressures in the market, especially with potential generic alternatives to its key treatment, Attruby, could significantly hinder revenue generation and market penetration.

BBIO has been analyzed by 22 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Pharma Inc (BBIO) Forecast

Analysts have given BBIO a Buy based on their latest research and market trends.

According to 22 analysts, BBIO has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Pharma Inc (BBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.